StreetInsider.com News Articles

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

Thu, 05 Feb 2026 04:53:00 -0400

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.

Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that:

The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.
This triggers the option to exercise Warrants.
Early, encouraging tumour shrinkage, and significant decrease in tumour biomarker CA 19-9 (>85% decrease, unaudited data).

OSLO, Norway, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Reference is made

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Tue, 24 Jun 2025 02:00:00 -0400

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer.

“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Tue, 24 Jun 2025 02:00:00 -0400

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Tue, 24 Jun 2025 02:00:00 -0400

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Tue, 24 Jun 2025 02:00:00 -0400

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with

EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

Tue, 20 May 2025 02:30:00 -0400

These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy
In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p<0.05)
Final analysis mirrors the excellent safety profile of PS101 seen in the interim read-out and suggests a dose-response relationship
The data supports the company’s plans for its Phase 2 trial (ENACT) in patients with locally advanced or borderline resectable pancreatic cancer

OSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT

EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

Tue, 20 May 2025 02:30:00 -0400

These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy
In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p<0.05)
Final analysis mirrors the excellent safety profile of PS101 seen in the interim read-out and suggests a dose-response relationship
The data supports the company’s plans for its Phase 2 trial (ENACT) in patients with locally advanced or borderline resectable pancreatic cancer

OSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT

EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

Tue, 20 May 2025 02:30:00 -0400

These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy
In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p<0.05)
Final analysis mirrors the excellent safety profile of PS101 seen in the interim read-out and suggests a dose-response relationship
The data supports the company’s plans for its Phase 2 trial (ENACT) in patients with locally advanced or borderline resectable pancreatic cancer

OSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT

EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

Tue, 20 May 2025 02:30:00 -0400

These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy
In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p<0.05)
Final analysis mirrors the excellent safety profile of PS101 seen in the interim read-out and suggests a dose-response relationship
The data supports the company’s plans for its Phase 2 trial (ENACT) in patients with locally advanced or borderline resectable pancreatic cancer

OSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model

Tue, 28 Jan 2025 13:36:00 -0400

MOUNTAIN VIEW, Calif. and OSLO, Norway, Jan. 28, 2025 /PRNewswire/ -- Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics' proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model

Tue, 28 Jan 2025 13:36:00 -0400

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model

Tue, 28 Jan 2025 13:36:00 -0400

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model

Tue, 28 Jan 2025 13:36:00 -0400

Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Fri, 03 Jan 2025 08:23:51 -0400

Piper Sandler analyst Yasmeen Rahimi weighs in on direct and indirect catalysts for selected Biotechnology companies.

The analyst said: "Into 2025, we updated our Vol. 2 direct/indirect catalyst tracker for our 35 covered companies following 3Q24 earnings and YE24. Accordingly, we outline ~190 direct and ~150+ in-direct catalysts (competitive MoAs/indications) and reference our Vol. 11 HCM, Vol. 6 MASH, and Vol. 14 obesity trackers. Importantly, our catalyst tracker is a useful source to ensure investors do not miss key inflection points across our coverage and strategically understand competitive dynamics for each of our covered stocks. Moreover, please reference our recent 2025